EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
Angelini Ventures has already invested €125 million in 22 startups
Angelini Ventures has already invested €125 million in 22 startups
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The formulation is backed by over 80 clinical trials and 200 scientific publications
Subscribe To Our Newsletter & Stay Updated